In patients with life-limiting illness and refractory dyspnea, what is the effectiveness of oxygen compared with room air delivered by nasal cannula for relief of breathlessness? Design: Randomized controlled trial. ClinicalTrials.govNCT00327873, Current Controlled Trials ISRCTN67448752. Allocation: Concealed.*Blinding: Blinded (patients, clinicians, and {clinic al research nurses} †).*Follow-up period: 7 days.Setting: Outpatient pulmonary, oncology, and primary care clinics in Australia, USA, and the UK.Patients: 239 patients > 18 years of age (mean age 74 y, 62% men) who had PaO2 > 7.3 kPa and refractory dyspnea related to life-limiting illness (≥ 3 on Medical Research Council categoricaldyspnea scale at rest or with negligible exertion), had received maximum treatment for nderlying disease, were expected to survive for ≥ 1 month, and were receiving stable medications the previous week. Exclusion criteria were eligibility for long-term oxygen therapy; history of hypercarbic respiratory failure with oxygen; anemia, hypercarbia, or cognitive impairment; smoking; or respiratory or cardiac event in the past 7 days.Intervention: 7 days of oxygen (n = 120) or room air (n = 119) delivered by a concentrator and nasal cannula at a continuous rate of 2 L/min. Patients were asked to use the concentrator for ≥ 15 h/d.Outcomes: Main outcome was "breathlessness right now" (rating scale from 0 to 10, 10 = "breathlessness as bad as you can imagine," assessed twice daily). Based on a sample size of 240, the study would have 80% power to detect a 1-point difference in breathlessness(α = 0.05). Pa tient follow-up: 88% of patients completed all 7 days of assessments.Main results: Oxygen and room air did not differ for morning or evening breathlessness (Table) .Conclusion: Oxygen and room air delivered by nasal cannula did not differ for relief of breathlessness in patients with life-limiting illness and refractory dyspnea.
